Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model

Mechanisms Underlying Connexin Hemichannel Activation in Disease

(2021) Raf Van Campenhout et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib

(2020) Anand Prakash Singh et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Variability in cardiac miRNA-122 level determines therapeutic potential of miRNA-regulated AAV vectors

(2020) Izabela Kraszewska et al.   Molecular Therapy-Methods & Clinical Development

Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway

(2020) Rosalinda Madonna et al.   Journal of Clinical Medicine

Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases

(2020) Ying Liu et al.   Cardiovascular Toxicology

The role of vimentin, Connexin-43 proteins, and oxidative stress in the protective effect of propranolol against clozapine-induced myocarditis and apoptosis in rats

(2020) Basel A. Abdel-Wahab et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Canonical and Non-Canonical Roles of Connexin43 in Cardioprotection

(2020) Olga M. Rusiecka et al.   Biomolecules

Heart and liver connexin expression related to the first stage of aging: A study on naturally aged animals

(2020) Stefania Moscato et al.   ACTA HISTOCHEMICA

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies

(2019) Fiona H Tan et al.   OncoTargets and Therapy

Overview of the Components of Cardiac Metabolism

(2019) Elizabeth A. Hausner et al.   DRUG METABOLISM AND DISPOSITION

Cx43 phosphorylation–mediated effects on ERK and Akt protect against ischemia reperfusion injury and alter the stability of the stress-inducible protein NDRG1

(2019) Joell L. Solan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin‐6–Mediated Changes in Connexin Expression

(2019) Pietro Enea Lazzerini et al.   Journal of the American Heart Association

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management

(2019) Susanne Saussele et al.   ACTA HAEMATOLOGICA

Connexin 26 Expression in Mammalian Cardiomyocytes

(2018) S. Moscato et al.   Scientific Reports

Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications

(2017) Luc Leybaert et al.   PHARMACOLOGICAL REVIEWS

Connexins and Disease

(2017) Mario Delmar et al.   Cold Spring Harbor Perspectives in Biology

High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy

(2016) Rosalinda Madonna et al.   Cardiovascular Diabetology

Gap junction mediated miRNA intercellular transfer and gene regulation: A novel mechanism for intercellular genetic communication

(2016) Liang Zong et al.   Scientific Reports

The varying faces of IL-6: From cardiac protection to cardiac failure

(2015) Jillian A. Fontes et al.   CYTOKINE

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Altered expression of connexin 43 and related molecular partners in a pig model of left ventricular dysfunction with and without dipyrydamole therapy

(2015) Silvia Del Ry et al.   PHARMACOLOGICAL RESEARCH

Thrombospondins, Potential Drug Targets for Cardiovascular Diseases

(2013) Erja Mustonen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Sex Differences in Cardiomyocyte Connexin43 Expression

(2011) Brian L Stauffer et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY